Chinese herb extract improves liver steatosis by promoting the expression of high molecular weight adiponectin in NAFLD rats
Chinese herb extract improves liver steatosis by promoting the expression of high molecular weight adiponectin in NAFLD rats
复制标题
DOI：
10.3892/mmr.2017.7284
复制
发表时间：
2017-10-01
影响因子：
3.4
通讯作者：
Deng, Xin
中科院分区：
文献类型：
--
作者：
Liu, Xudong;Tong, Wangxia;Deng, Xin
高分子量脂联素(APN)与脂肪肝的发生发展密切相关，受AKT/Forkhead box Protein O1(FOXO1)途径的二硫键A氧化还原酶样蛋白(DsbA-L)调控。中草药提取物QSHX用于治疗肝病。本研究旨在探讨清肝消对非酒精性脂肪性肝病(NAFLD)的作用及其机制。以高脂高糖饲料喂养20周建立大鼠NAFLD模型。从第13周开始，给大鼠灌胃清热散或生理盐水，共8周。用放射免疫法测定肝功能、血脂和血浆APN。病理组织学染色后测量肝组织评分。免疫印迹法检测AKT、FOXO1、DsbA-L和HMW APN在大鼠脂肪组织和原代脂肪细胞中的表达和活性。结果表明，清肝消能显著降低NAFLD大鼠体重、肝脏指数和血清天冬氨酸氨基转移酶、丙氨酸氨基转移酶、甘油三酯水平，升高血清APN水平。治疗8周后，肝组织脂肪变性明显改善，肝脂肪变性积分明显降低。免疫印迹分析结果表明，清肾消可促进脂肪组织和原代脂肪细胞中DsbA-L和HMW APN的表达，降低磷酸化FOXO1和FOXO1的表达水平。结论：清肝消通过促进脂肪细胞HMW APN和DsbA-L的表达而减轻肝脏脂肪变性，其作用机制可能与抑制脂肪细胞FOXO1的活化和表达有关。
High molecular weight (HMW) adiponectin (APN) is closely correlated with the development of fatty liver and is modulated by the Akt/forkhead box protein O1 (FOXO1) pathway through disulfide-bond A oxidoreductase-like protein (DsbA-L). The Chinese herb extract, QSHX, is used to treat liver diseases. The present study investigated the effects of QSHX on non-alcoholic fatty liver disease (NAFLD) and its underlying mechanism. A rat model of NAFLD was established by feeding of a high-fat and high-sugar diet for 20 weeks. From week 13, the rats were administered with QSHX, or saline as a control, for 8 weeks. The liver function, blood fat and plasma APN were measured using a radioimmunoassay. The hepatic tissue score was measured following staining for pathology. The expression and activities of Akt, FOXO1, DsbA-L and HMW APN in the adipose tissue and primary adipocytes of the rats were measured using western blot analysis. It was found that QSHX significantly decreased the body weight, liver index, and serum levels of aspartate aminotransferase, alanine aminotransferase and triglyceride; and increased the serum level of APN in the NAFLD rats. Following 8 weeks of treatment with QSHX, the hepatic steatosis in the liver tissue improved and the score of hepatic steatosis was significantly decreased. The results of the western blot analysis indicated that QSHX promoted the expression of DsbA-L and HMW APN, and reduced the expression levels of phosphorylated FOXO1 and FOXO1 in adipose tissue and primary adipocytes. It was concluded that QSHX reduced hepatic steatosis by promoting the expression of HMW APN and DsbA-L, which may have been induced by inhibiting the activation and expression of FOXO1 in adipocytes.